Study to evaluate the efficacy of Parikara Yoga (An Ayurvedic polyherbal formulation) and Dietary regimen in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)

A Randomized placebo controlled trial to evaluate the efficacy Of Parikara Yoga and Pathya in the Management of Yakrita Roga with special reference to Non-Alcoholic Fatty Liver Disease. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/055977

Enrollment

Registered

2023-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: K760- Fatty (change of) liver, not elsewhere classified Health Condition 3: K77- Liver disorders in diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex of age group >18years and finding suggestive of fatty liver grade 1,2 and 3. 2.Non-Alcoholic or patients with history of alcohol addiction less than 20gm per day in men and 10 gm per day in women. 3. Clinical sign and symptoms suggesting of Yakrita Roga/NAFLD that is, pain in right upper quadrant/ epigastric region of abdomen, feeling of nausea, heaviness in abdomen, flatulence ,loss of appetite and burning sensation in abdomen if any. 4. Patients with normal serum bilirubin level and ALT/AST level less than 1.5 times of normal limit. 5. Patients with/without raised lipid profile.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Patients with history of diabetes mellitus, autoimmune hepatitis, drug abuse, chronic Hepatitis, raised ALT/AST level more than 1.5 times of normal limit. 3. Patients with complications of metabolic syndrome such as cerebrovascular accident, myocardial infarction, chronic kidney diseases, suffering from cirrhosis, ascites, variceal haemorrhage, coagulopathy, hepatorenal syndrome 4. Patient have any kind of malignancy.

Design outcomes

Primary

Measure	Time frame
Changes in USG findings and grading at the end of 56 daysTimepoint: Changes in USG findings and grading at the end of 56 days	—

Secondary

Measure	Time frame
1.Changes in liver function test, lipid profile at the and of 56 days 2. Changes in clinical sign and symptoms if any at the end of 60 daysTimepoint: At the end of 56 days	—

Countries

India

Contacts

Public ContactDr Gaurav Kumar Garg

National Institute Of Ayurveda ,Deemed to be University, Jaipur

gauravdrgarg@gmail.com7988890284

Outcome results